- Home
- GNRC vs EXEL Comparison
GNRC vs EXEL Comparison
Compare GNRC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNRC
- EXEL
- Stock Information
- Founded
- GNRC 1959
- EXEL 1994
- Country
- GNRC United States
- EXEL United States
- Employees
- GNRC N/A
- EXEL N/A
- Industry
- GNRC Metal Fabrications
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNRC Consumer Discretionary
- EXEL Health Care
- Exchange
- GNRC Nasdaq
- EXEL Nasdaq
- Market Cap
- GNRC 10.8B
- EXEL 10.4B
- IPO Year
- GNRC 2010
- EXEL 2000
- Fundamental
- Price
- GNRC $181.43
- EXEL $40.44
- Analyst Decision
- GNRC Buy
- EXEL Buy
- Analyst Count
- GNRC 18
- EXEL 22
- Target Price
- GNRC $179.33
- EXEL $44.00
- AVG Volume (30 Days)
- GNRC 811.7K
- EXEL 2.3M
- Earning Date
- GNRC 10-30-2025
- EXEL 10-28-2025
- Dividend Yield
- GNRC N/A
- EXEL N/A
- EPS Growth
- GNRC 54.62
- EXEL 81.76
- EPS
- GNRC 6.03
- EXEL 2.08
- Revenue
- GNRC $4,411,654,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- GNRC $5.66
- EXEL $9.19
- Revenue Next Year
- GNRC $8.28
- EXEL $12.54
- P/E Ratio
- GNRC $30.16
- EXEL $19.56
- Revenue Growth
- GNRC 9.69
- EXEL 10.73
- 52 Week Low
- GNRC $99.50
- EXEL $25.17
- 52 Week High
- GNRC $203.25
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- GNRC 47.24
- EXEL 62.26
- Support Level
- GNRC $179.69
- EXEL $38.37
- Resistance Level
- GNRC $192.72
- EXEL $39.27
- Average True Range (ATR)
- GNRC 4.71
- EXEL 1.03
- MACD
- GNRC -1.00
- EXEL 0.38
- Stochastic Oscillator
- GNRC 39.61
- EXEL 92.53
About GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.